chrX-120626654-G-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_001011551.3(C1GALT1C1):c.513C>A(p.His171Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000108 in 1,207,282 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 7 hemizygotes in GnomAD. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000018 ( 0 hom., 2 hem., cov: 24)
Exomes 𝑓: 0.000010 ( 0 hom. 5 hem. )
Consequence
C1GALT1C1
NM_001011551.3 missense
NM_001011551.3 missense
Scores
1
6
10
Clinical Significance
Conservation
PhyloP100: 0.441
Genes affected
C1GALT1C1 (HGNC:24338): (C1GALT1 specific chaperone 1) This gene encodes a type II transmembrane protein that is similar to the core 1 beta1,3-galactosyltransferase 1, which catalyzes the synthesis of the core-1 structure, also known as Thomsen-Friedenreich antigen, on O-linked glycans. This gene product lacks the galactosyltransferase activity itself, but instead acts as a molecular chaperone required for the folding, stability and full activity of the core 1 beta1,3-galactosyltransferase 1. Mutations in this gene have been associated with Tn syndrome. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Dec 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High Hemizygotes in GnomAd4 at 2 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
C1GALT1C1 | NM_001011551.3 | c.513C>A | p.His171Gln | missense_variant | 2/2 | ENST00000304661.6 | |
C1GALT1C1 | NM_152692.5 | c.513C>A | p.His171Gln | missense_variant | 3/3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
C1GALT1C1 | ENST00000304661.6 | c.513C>A | p.His171Gln | missense_variant | 2/2 | 1 | NM_001011551.3 | P1 | |
C1GALT1C1 | ENST00000371313.2 | c.513C>A | p.His171Gln | missense_variant | 3/3 | 1 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000179 AC: 2AN: 111939Hom.: 0 Cov.: 24 AF XY: 0.0000586 AC XY: 2AN XY: 34131
GnomAD3 genomes
AF:
AC:
2
AN:
111939
Hom.:
Cov.:
24
AF XY:
AC XY:
2
AN XY:
34131
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000278 AC: 5AN: 180159Hom.: 0 AF XY: 0.0000616 AC XY: 4AN XY: 64923
GnomAD3 exomes
AF:
AC:
5
AN:
180159
Hom.:
AF XY:
AC XY:
4
AN XY:
64923
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000100 AC: 11AN: 1095343Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 5AN XY: 361097
GnomAD4 exome
AF:
AC:
11
AN:
1095343
Hom.:
Cov.:
31
AF XY:
AC XY:
5
AN XY:
361097
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000179 AC: 2AN: 111939Hom.: 0 Cov.: 24 AF XY: 0.0000586 AC XY: 2AN XY: 34131
GnomAD4 genome
AF:
AC:
2
AN:
111939
Hom.:
Cov.:
24
AF XY:
AC XY:
2
AN XY:
34131
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
4
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 08, 2023 | The c.513C>A (p.H171Q) alteration is located in exon 3 (coding exon 1) of the C1GALT1C1 gene. This alteration results from a C to A substitution at nucleotide position 513, causing the histidine (H) at amino acid position 171 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
T;T
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;T
M_CAP
Benign
T
MetaRNN
Uncertain
D;D
MetaSVM
Benign
T
MutationAssessor
Benign
L;L
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D
REVEL
Benign
Sift
Benign
T;T
Sift4G
Uncertain
T;T
Polyphen
D;D
Vest4
MutPred
Loss of catalytic residue at H171 (P = 0.0265);Loss of catalytic residue at H171 (P = 0.0265);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at